Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × NSCLC × Docetaxel × Clear all

Phase

Phase 3 2 Phase NA 1 Phase 4 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Prostatic Neoplasms 4 Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Breast Neoplasms, Male 2 Uterine Neoplasms 1 Thrombosis 1 Peritoneal Neoplasms 1 Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Infections 1 Hormone Refractory Prostate Cancer 1 Head and Neck Neoplasms 1 Drug-Related Side Effects and Adverse Reactions 1 Carcinogenesis 1 Breast Neoplasm Female 1 Breast Diseases 1 Amenorrhea 1 Adenocarcinoma 1

Interventions

sugemalimab 1 spartalizumab 1 Vinorelbine 1 Radiotherapy 1 Pemetrexed 1 Paclitaxel 1 Liquid Biopsy 1 Gemcitabine 1 Gefitinib 1 Erlotinib Hydrochloride 1 Drug Therapy 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06576635 2026-01-20

LUNG-05

University of Illinois at Chicago

Phase NA Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡